<DOC>
	<DOCNO>NCT00153907</DOCNO>
	<brief_summary>The purpose study find high dose capecitabine oral navelbine give without cause severe side effect , determine safety , tolerability , effect ( good bad ) capecitabine give oral navelbine patient advance breast cancer .</brief_summary>
	<brief_title>Navelbine Capecitabine Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>- Not every patient receive dose capecitabine navelbine . A small group enrol onto study give certain dos drug . If tolerate well ( easily manageable side effect ) , next small group people enrol receive high dose one drug . This continue find high dos drug give without cause serious unmanageable side effect . - Patients give oral navelbine day 1 8 cycle , unless high dose . In case , give navelbine day 1 , 8 15 . Capecitabine give day 1-14 cycle two divide dos approximately 12 hour apart . - While patient study follow test procedure perform : physical examination every 3 week ; routine blood work every week ; extensive laboratory test every 3 week ; disease status check every 6 week ( 2 cycle ) unless symptoms disease progression . - The weekly treatment continue unless disease progression unacceptable side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically confirm breast cancer evidence locally advance metastatic disease Female patient age 18 old No three prior chemotherapeutic regimen metastatic set ANC &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 SGOT &lt; 3 x ULN Bilirubin &lt; 1.5 x ULN Performance status 0 1 At least 3 week since prior chemotherapy 2 week since prior radiation , surgery anticancer investigational agent Able swallow retain oral medication Measurable disease Prior vinca alkaloid Active gastrointestinal disease disorder Pregnant lactate Serious comorbid medical psychological condition Prior bone marrow stem cell transplant Prior document severe sensitivity 5FU</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Xeloda</keyword>
	<keyword>Navelbine</keyword>
	<keyword>capecitabine</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>